Europe Edges Toward New HTA Understanding The European Union is moving ahead, in its own slightly crabwise fashion, with its attempts to work out what healthcare budgets should be used for. It has been flirting with health technology assessment (HTA) for some time now, but for a long while the relationship was conducted in the EU's usual hands-off "don't look at me while I'm doing this" approach to pharmaceuticals and money. Reflector reports... Read more
GSK and Novo Nordisk Lead on Access to Medicines Index Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries. For the fourth time, GSK leads the index with Novo Nordisk taking second. J&J. Novartis, Gilead and Merck KGaA rank three to six with nearly even scores... Read more
Europe 2015: The year of Living Openly Companies’ commitment to open and clear processes will become all the more important as European regulators’ new emphasis on transparency and harmonization intensifies in 2015, writes Dakshayini Kulkarni... Read more
Pharm Exec's 2015 Pipeline Report This year's pipeline report checks in on the emerging technologies, as well as potential therapies to address metabolic and neurodegenerative diseases. There's a lot to like in the pipeline and more than a little competitive drama to make it really interesting. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers? .... Read more
Which of the following activities is your most important upcoming initiative?
